IFRX - CONSENSUS CO - InflaRx N.V.

InflaRx N.V. (IFRX) focuses on the global advancement of small molecules to combat inflammation, aiming to capture a niche within the hospital segment. Market price action confirms this trajectory, with the consensus standing at 7.93. Business stability depends on the remaining cash runway prior to the certification of drugs for orphan diseases. Currently, the German biotech is developing its own therapy portfolio through collaboration with US suppliers.

For the biopharmaceutical InflaRx N.V. (IFRX), which adheres to standard environmental regulations in its laboratories, the analysts' calculated price target reflects the market valuation of its development potential. This metric aggregates the average price expectations of experts, allowing investors to identify the gap between the current quote and the business's fundamental value through daily price action, where peak indicator values may signal that the asset is overbought.